Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a new immunotherapy stop smoldering myeloma before it becomes active cancer?

NCT ID NCT05469893

Recruiting now Disease control Sponsor: Irene Ghobrial, MD Source: ClinicalTrials.gov ↗

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This phase II trial compares the anti-cancer activity of teclistamab, an immunotherapy, against the standard combination of lenalidomide and dexamethasone in people with high-risk smoldering multiple myeloma. Smoldering myeloma is a pre-cancerous condition that often progresses to active multiple myeloma, but no treatments are currently approved for it. The study aims to see if early intervention can improve outcomes, such as complete response rates and progression-free survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
teclistamab, lenalidomide, and dexamethasone
What this could lead to
If successful, this trial could provide an effective early treatment option for people with high-risk smoldering myeloma, potentially delaying or preventing progression to active multiple myeloma.
What could go wrong
This is a phase II study with a small number of participants, so results may not apply broadly. Teclistamab and lenalidomide can cause significant side effects, and the trial may not show a clear benefit over current approaches.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH RISK SMOLDERING MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma Smoldering Multiple Myeloma smoldering plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIGH RISK SMOLDERING MULTIPLE MYELOMA MULTIPLE MYELOMA SMOLDERING MULTIPLE MYELOMA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Colorado Blood Cancer Institute

    RECRUITING

    Denver, Colorado, 80218, United States

    Contact Email: •••••@•••••

  • Dana Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02115, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Oregon Health & Science University

    RECRUITING

    Portland, Oregon, 97239, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.